4Y5X image
Deposition Date 2015-02-12
Release Date 2015-03-18
Last Version Date 2024-11-06
Entry Detail
PDB ID:
4Y5X
Title:
Diabody 305 complex with EpoR
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.15 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 41 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:diabody 310 VL domain
Chain IDs:A, D, G, J
Chain Length:136
Number of Molecules:4
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:diabody 310 VH domain
Gene (Uniprot):V1-11
Chain IDs:B, E, H, K
Chain Length:116
Number of Molecules:4
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Erythropoietin receptor
Gene (Uniprot):EPOR
Chain IDs:C, F, I, L
Chain Length:229
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands.
Cell 160 1196 1208 (2015)
PMID: 25728669 DOI: 10.1016/j.cell.2015.02.011

Abstact

Most cell-surface receptors for cytokines and growth factors signal as dimers, but it is unclear whether remodeling receptor dimer topology is a viable strategy to "tune" signaling output. We utilized diabodies (DA) as surrogate ligands in a prototypical dimeric receptor-ligand system, the cytokine Erythropoietin (EPO) and its receptor (EpoR), to dimerize EpoR ectodomains in non-native architectures. Diabody-induced signaling amplitudes varied from full to minimal agonism, and structures of these DA/EpoR complexes differed in EpoR dimer orientation and proximity. Diabodies also elicited biased or differential activation of signaling pathways and gene expression profiles compared to EPO. Non-signaling diabodies inhibited proliferation of erythroid precursors from patients with a myeloproliferative neoplasm due to a constitutively active JAK2V617F mutation. Thus, intracellular oncogenic mutations causing ligand-independent receptor activation can be counteracted by extracellular ligands that re-orient receptors into inactive dimer topologies. This approach has broad applications for tuning signaling output for many dimeric receptor systems.

Legend

Protein

Chemical

Disease

Primary Citation of related structures